Method for determining combination of specific sequence and biological target in DNA coding compound library screening
By introducing merger sequences into the DNA-encoded compound library and using computer coding methods, false positive signals in the screening of the DNA-encoded compound library are identified and eliminated, the false positive problems caused by the interaction between DNA tags and biological targets are solved, and the accuracy of screening is improved Sex and efficiency.
Patent Information
- Application Number
- CN202410883624.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2019-09-24
- Filing Date
- 2020-09-24
- Publication Date
- 2024-11-12
AI Technical Summary
In the existing DNA-encoding compound library screening technology, false positive signals are caused by the interaction between DNA tags and biological targets, which affects the accuracy and efficiency of screening data. The existing methods have a long time to build a control library and are costly, making it difficult to completely eliminate it. False positive signal.
By introducing merger sequences into the DNA-encoded compound library, the merger sequence analyzes specific sequences bound to biological targets, identify and label the random noise signals in the screening signal of the DNA-encoded compound library, and perform cluster analysis and sequence ratios through computer coding methods Yes, a specific sequence that binds to a biological target is determined and false positive signals are excluded.
It improves the accuracy of the screening of DNA-encoded compound library, reduces false positive signals, improves screening efficiency and economicality, and enhances the application value of DNA-encoded compound library technology.
Smart Images

Figure HDA0004925326600000011 
Figure HDA0004925326600000021 
Figure HDA0004925326600000031
Abstract
Description
[0001] This application is a divisional application for the invention patent with application number 202010994324.7 and application date September 24, 2020. Technical Field
[0002] The invention discloses an analytical method for determining the binding of a specific sequence with a biological target in the screening of a DNA-encoded compound library. Background Art
[0003] In the field of new drug research and development, high-throughput screening for biological targets is one of the main means to quickly obtain lead compounds. However, traditional high-throughput screening based on single molecules takes a long time, requires huge equipment investment, and has a limited number of library compounds (millions). In addition, the construction of a compound library requires decades of accumulation, which limits the efficiency and possibility of discovering lead compounds. The DNA-encoded compound library technology (WO2005058479, WO2018166532, CN103882532) that has emerged in recent years combines combinatorial chemistry and molecular biology techniques. By connecting a fragment compound with a unique sequence of DNA (usually called DNA encoding) at the molecular level, the "combination-split" strategy of combinatorial chemistry is used to quickly construct a huge number of compound libraries through two to more cycles. The scale of the DNA-encoded compound library currently used in industry can reach hundreds of billions to trillions, and can be identified by screening and sequencing methods. This technology makes the screening of lead compounds faster and more efficient than ever before, becoming the trend of the next generation of compound library screening technology. It has begun to be widely used in the pharmaceutical industry and has produced many positive effects (Accounts of Chemical Research, 2014, 47, 1247-1255).
[0004] However, since DNA-encoded compounds all carry DNA tags, and some biological targets (such as RNA) may interact with DNA tags, false positive signals may be generated in the screening data, interfering with the extraction and interpretation of real signals. There are currently methods that have not been publicly reported in the literature to help identify such signals. The specific approach is to construct a DNA library with the same DNA tag but without small molecules as a control, and perform data analysis after screening. However, this method requires rebuilding the library, which takes a long time and is costly, and it is difficult to make the constructed DNA library completely consistent with the DNA tag of the original library, which limits the application of this method. Therefore, developing a method that can quickly and economically determine false positive signals that may be caused by DNA tags for such biological targets can further enhance the application value of DNA-encoded compound library screening technology.
[0005] Barry et al. disclosed a DNA-encoded compound in WO2006135786, in which a capping sequence is introduced into the DNA portion, and the capping sequence is a DNA sequence containing degenerate bases. By screening and analyzing the degenerate bases, it is possible to determine whether the signal is the result of PCR replication (same sequence) or an independently occurring compound (different sequence), thereby reducing false positive signals in the data. Summary of the invention
[0006] In order to solve the above problems, the present invention provides an analytical method for determining the binding of a specific sequence with a biological target in the screening of a DNA-encoded compound library. By the method of the present invention, false positive signals that may be generated by the binding of a specific DNA sequence with a biological target in the screening signal of the DNA-encoded compound library can be found, thereby improving the accuracy of the screening of DNA-encoded compounds.
[0007] The present invention provides an analytical method for determining the binding of a specific sequence with a biological target in the screening of a DNA-encoded compound library, comprising analyzing the specific sequence binding with the biological target through DNA degenerate sequence analysis in the screening signal of the DNA-encoded compound library.
[0008] Furthermore, the DNA portion of the DNA encoding the compound contains a degenerate sequence.
[0009] Furthermore, the degenerate sequence is a completely random base sequence or a partially random base sequence with a length of 4 to 16.
[0010] Furthermore, before the specific sequence binding to the biological target is analyzed by DNA degenerate sequence, random noise signals in the screening signal of the DNA-encoded compound library are identified.
[0011] Furthermore, the method for identifying random noise signals in screening signals of a DNA-encoded compound library is as follows: the copy number of each DNA tag after screening is calculated, and DNA tag signals with a copy number not higher than N are marked as random noise signals.
[0012] More specifically, N is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.
[0013] Furthermore, the method for analyzing the specific sequence binding to the biological target is: performing cluster analysis on the degenerate sequence signals, and determining the specific sequence binding to the biological target according to the cluster analysis results.
[0014] The present invention also provides a computer coding method for determining the binding of a specific sequence in a DNA-encoded compound library to a biological target, comprising: extracting a degenerate sequence region on a DNA-encoded sequence by a degenerate sequence extraction module, and performing cluster analysis on the degenerate sequence by a cluster analysis module.
[0015] Furthermore, the computer coding method also includes: using a sequence assembly / alignment analysis module to stitch the degenerate sequences in the cluster into overlapping groups, then aligning the degenerate sequences in the corresponding cluster with the overlapping groups and calculating the coverage depth of each base of the overlapping groups.
[0016] Furthermore, the computer coding method also includes: extracting the top 1% to 20% of the coverage depth ranking region through a motif prediction module, and marking the region sequence whose probability of occurrence of the given region sequence in the target group and the control group combined sequence changes by more than 5 to 20 times as a motif that binds to the target.
[0017] The DNA portion of the DNA-encoded compound described in the present invention at least includes a DNA tag portion and a DNA degenerate sequence portion, wherein the DNA tag portion is used to mark the corresponding compound structure.
[0018] In the present invention, "edit distance" means that if sequence A needs to change at least M bases to become sequence B, then the edit distance between A and B is M.
[0019] In the present invention, "overlapping group" refers to a continuous sequence formed by splicing similar fragments in the sequence.
[0020] In the present invention, "coverage depth" refers to the number of times each base in the overlapping sequence is covered by the degenerate sequence in the alignment result.
[0021] The target described in the present invention is specifically a biological target (such as RNA, etc.) that may have potential binding to DNA. When using a DNA-encoded compound library to screen this type of target, the method of the present invention can be used to predict and determine the DNA binding motif and mark false positive signals that may bind to DNA. The "DNA binding motif" refers to a DNA sequence that has a binding effect on a certain biological target.
[0022] The method described in the present invention is based on the analysis of the screening data of the DNA-encoded compound library, and further analyzes all the decoded sequences.
[0023] Obviously, according to the above contents of the present invention, in accordance with common technical knowledge and customary means in the art, without departing from the above basic technical ideas of the present invention, other various forms of modification, replacement or change may be made.
[0024] The above contents of the present invention are further described in detail below through specific implementation methods in the form of embodiments. However, this should not be understood as the scope of the above subject matter of the present invention being limited to the following examples. All technologies realized based on the above contents of the present invention belong to the scope of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS
[0025] Figure 1The present invention is a specific data processing flow chart of the method.
[0026] Figure 2 Schematic diagram of different enrichment levels of motif sequences determined by the method of the present invention in Example 1 in the RNA target group and control group data. Each point in the scatter plot represents a degenerate sequence, and the percentage of its enrichment level in the target group and the control group is marked on the X-axis and Y-axis, respectively. All degenerate sequences with significantly higher content in the target group than in the control group contain the determined DNA binding motif (black square points).
[0027] Figure 3 The signal distribution before (top) and after (bottom) the removal of false positive signals marked as DNA binding by the method of the present invention in Example 1. The X-axis represents different DNA-encoded compound libraries, and the Y-axis represents signal intensity.
[0028] Figure 4 This is a schematic diagram of the enrichment degree of a protein target known to not bind to DNA and the control group data verified by the method of the present invention in Example 2.
[0029] Figure 5 The left figure is a schematic diagram of the different enrichment levels of the motif sequence determined by the method of the present invention in Example 3 in the target group and the control group data; the right figure is a schematic diagram of the sequence of the TAR RNA target used for screening in Example 3.
[0030] Figure 6 Schematic diagram of the different enrichment levels of the motif sequence determined by the method of the present invention in Example 4 in the target group and the control group data. DETAILED DESCRIPTION
[0031] Example 1: Determining the DNA binding motif of an RNA target
[0032] A DNA-encoded compound library was constructed according to the method described in WO2018166532, wherein the DNA portion contained a 10 bp-long degenerate base. RNA targets and a blank control group were screened according to the DNA-encoded compound library screening method described in WO2018166532, and signal data was extracted after sequencing. Figure 1 The data processing is performed according to the flowchart shown.
[0033] The degenerate sequence extraction module extracts the degenerate sequence of the DNA part of the compound with a DNA tag copy number of 1 or 2. The cluster analysis module calculates the edit distance of all extracted degenerate sequences. All degenerate sequences are clustered. The sequence assembly / alignment analysis module splices the degenerate sequences in the top three clusters in cluster size into overlapping groups, and then aligns the degenerate sequences in the corresponding clusters with the overlapping groups and calculates the coverage depth of each base of the overlapping groups. After the motif prediction module extracts the top 10% of the regions in the coverage depth ranking, if the multiple change of the probability of occurrence of the degenerate sequence in the target group and the control group exceeds 10 times, the sequence of the region is marked as a motif sequence that binds to the target. The motif feedback scoring module compares the predicted motif sequence with the DNA tags of all compounds that are not marked as noise and scores according to the alignment results. In this embodiment, the perfect match score is marked as 2, the mismatch score is marked as -3, the introduction of insertion and deletion score is marked as -5, and the extension of insertion and deletion score is marked as -2. Enrichment signals with scores higher than 0.6 after dividing the hypothetical perfect match score will be marked as false positive signals generated by the binding of a specific DNA sequence to the biological target.
[0034] like Figure 3 As shown, there are a large number of false positive signals in the screening signals of this embodiment due to the binding of DNA to RNA targets. Marking and excluding false positive signals can improve the accuracy of the screening results of the DNA-encoded compound library.
[0035] Example 2: Verifying whether a protein target known to not bind to DNA has a DNA binding motif
[0036] According to the same method as in Example 1, the percentage of the degenerate sequence content in the noise signal of the target group and the control group data is marked on the X-axis and Y-axis respectively. Figure 4 As shown, there is no significantly enriched motif sequence in the protein target screening signal, and the screening signal does not contain false positive signals caused by the binding of the DNA sequence to the target.
[0037] Example 3: Determination of false positive signals due to DNA-RNA binding in DEL screening using TAR RNA (Trans-activator response region RNA) as a target
[0038] According to the same method as in Example 1, the percentage of the degenerate sequence content in the noise signal of the TAR RNA group and the blank control group is marked on the X-axis and Y-axis respectively. Figure 5As shown in the figure, the target group is enriched with a large number of DNA fragments. Analysis of several specific sequences with the highest ratio of DNA fragments enriched in the target group / control group showed that all specific sequences were related to the hairpin region (highlighted region) sequence of TAR RNA. In addition, there are a large number of sequences whose enrichment in the target group samples is 10 times higher than that in the blank control group. By identifying the signals enriched with such base sequences in the DEL screening results, false positive signals caused by DNA-RNA binding enrichment can be better excluded.
[0039] Example 4: Identification of DNA binding motifs in DEL screening for helicases with DNA binding domains
[0040] According to the same method as in Example 1, the percentage of the degenerate sequence content in the noise signal of the helicase group and the blank control group is marked on the X-axis and Y-axis respectively. Figure 6 As shown in the figure, the overall distribution of DNA fragments in the target group and the control group is relatively similar. However, the enrichment of some sequences with higher AT content in the target group is slightly higher than that in the control group, indicating that the target may have binding properties to DNA fragments with lower GC content in DEL screening.
Claims
1. A computer coding method for determining the binding of a specific sequence in a DNA-encoded compound library to a biological target, characterized in that: The degenerate sequence regions on the DNA coding sequence are extracted by the degenerate sequence extraction module, and the degenerate sequences are clustered and analyzed by the cluster analysis module.
2. The method according to claim 1, characterized in that: The computer coding method also includes: using a sequence assembly / alignment analysis module to stitch the degenerate sequences in the cluster into overlapping groups, then aligning the degenerate sequences in the corresponding cluster with the overlapping groups and calculating the coverage depth of each base of the overlapping groups.
3. The method according to claim 2, characterized in that: The computer coding method also includes: extracting the top 1% to 20% of the coverage depth ranking region through a motif prediction module, and marking the region sequence whose probability of occurrence of the given region sequence in the target group and the control group combined sequence changes by more than 5 to 20 times as a motif that binds to the target.
Citation Information
Patent Citations
Methods for synthesis of encoded libraries
WO2005058479A2
Methods for synthesis of encoded libraries
WO2006135786A2
Methods and compositions for synthesis of encoded libraries
WO2018166532A1
Low-frequency gene fusion detection method and device
CN106676182A
Multiplex PCR primer, kit and method for targeted sequencing detection of lung cancer gene based on UMI single molecular tag denoising technology
CN109266744A
